Insights and Updates: New Data on Next-Generation Retinal Treatments
Durga Borkar, MD, MMCi
Veeral Sheth, MD, MBA, FASRS, FACS
Why CELMoDs Matter in Myeloma
Sagar Lonial, MD, FACP
Data Dive: Clinical Evidence Behind CELMoDs
Precision Targeting: Matching CELMoDs to the Right Patient With Myeloma
Noopur Raje, MD
Real-World Ready: Practical Tips for Community Oncologists
Joshua Richter, MD
Next-Generation Innovations: The Future of CELMoDs in Myeloma
Mastering the Sequence: CELMoDs Across Treatment Lines
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
John M. Kirkwood, MD
Sapna Patel, MD
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Community Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
Robert J. Motzer, MD
Elizabeth R. Plimack, MD, MS, FASCO
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Kevin Kalinsky MD, MS
Komal Jhaveri, MD, FACP
HER2 in Bladder Cancer: Breaking Through the Molecular Frontier
Vadim S. Koshkin, MD
Advancing Myasthenia Gravis (MG) Treatment Through Guideline Updates and Emerging Therapies
October 30, 2025
San Francisco, California
What’s New In Glaucoma?
Paul Petrakos, DO, MS
Justin Schweitzer, OD, FAAO
I. Paul Singh, MD
Sarah H. Van Tassel, MD
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.